NCT05099536 is a Phase 1 clinical trial of 3D011-08 in Solid Tumor, Adult, sponsored by 3D Medicines (Beijing) Co., Ltd..

Who is sponsoring NCT05099536?

NCT05099536 is sponsored by 3D Medicines (Beijing) Co., Ltd..

What drugs are being tested in NCT05099536?

Interventions in NCT05099536: 3D011-08.

What condition does NCT05099536 study?

NCT05099536 studies Solid Tumor, Adult.

Is NCT05099536 still recruiting?

NCT05099536 is currently withdrawn. Last updated 31 January 2024.

Last reviewed 2024-01-31 · How we verify

NCT05099536

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Withdrawn Phase 1 Last updated 31 January 2024

What this trial tests

Phase 1 trial testing 3D011-08 in Solid Tumor, Adult. Withdrawn.

Timeline

24 February 2022

Primary endpoint
11 September 2023

11 September 2023

Quick facts

Lead sponsor	3D Medicines (Beijing) Co., Ltd.
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Start date	24 February 2022
Primary completion	11 September 2023
Estimated completion	11 September 2023
Sites	1 location across China

Drugs / interventions tested

3D011-08 — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

3D Medicines (Beijing) Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other 3D Medicines (Beijing) Co., Ltd. trials

Trials by the same sponsor.

NCT04221204 — A Monotherapy in Subjects With Advanced Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05099536 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 3D Medicines (Beijing) Co., Ltd.
Last refreshed: 31 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05099536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing